Mutual of America Capital Management LLC Has $3.19 Million Stock Holdings in Teleflex Incorporated $TFX

Mutual of America Capital Management LLC trimmed its position in Teleflex Incorporated (NYSE:TFX) by 7.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,920 shares of the medical technology company’s stock after selling 2,201 shares during the period. Mutual of America Capital Management LLC’s holdings in Teleflex were worth $3,186,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Thompson Investment Management Inc. raised its position in shares of Teleflex by 2.1% in the 2nd quarter. Thompson Investment Management Inc. now owns 4,970 shares of the medical technology company’s stock valued at $588,000 after acquiring an additional 100 shares during the period. CX Institutional raised its position in shares of Teleflex by 14.7% in the 2nd quarter. CX Institutional now owns 872 shares of the medical technology company’s stock valued at $103,000 after acquiring an additional 112 shares during the period. Signaturefd LLC raised its position in shares of Teleflex by 38.3% in the 1st quarter. Signaturefd LLC now owns 433 shares of the medical technology company’s stock valued at $60,000 after acquiring an additional 120 shares during the period. Empirical Finance LLC raised its position in shares of Teleflex by 7.9% in the 1st quarter. Empirical Finance LLC now owns 1,690 shares of the medical technology company’s stock valued at $234,000 after acquiring an additional 124 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Teleflex by 30.2% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 556 shares of the medical technology company’s stock valued at $77,000 after acquiring an additional 129 shares during the period. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Teleflex

In other Teleflex news, Director Stuart A. Randle purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The stock was bought at an average cost of $115.86 per share, with a total value of $115,860.00. Following the purchase, the director directly owned 7,547 shares of the company’s stock, valued at $874,395.42. The trade was a 15.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jaewon Ryu purchased 1,500 shares of the firm’s stock in a transaction dated Tuesday, August 5th. The shares were acquired at an average cost of $115.00 per share, with a total value of $172,500.00. Following the completion of the purchase, the director directly owned 3,727 shares in the company, valued at approximately $428,605. This represents a 67.36% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 5,500 shares of company stock worth $633,590. 1.40% of the stock is currently owned by corporate insiders.

Teleflex Price Performance

Shares of TFX opened at $132.06 on Friday. The stock has a market capitalization of $5.84 billion, a P/E ratio of 31.07, a P/E/G ratio of 1.85 and a beta of 1.05. Teleflex Incorporated has a twelve month low of $108.90 and a twelve month high of $239.46. The company has a 50 day moving average of $126.06 and a 200-day moving average of $123.65. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.36 by $0.37. The company had revenue of $780.90 million during the quarter, compared to analysts’ expectations of $771.53 million. Teleflex had a net margin of 6.31% and a return on equity of 15.08%. The business’s quarterly revenue was up 4.2% on a year-over-year basis. During the same period last year, the business earned $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, equities research analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 15th. Stockholders of record on Friday, August 15th were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, August 15th. Teleflex’s dividend payout ratio (DPR) is currently 32.00%.

Analyst Upgrades and Downgrades

TFX has been the topic of a number of analyst reports. Mizuho increased their price target on shares of Teleflex from $130.00 to $135.00 and gave the company a “neutral” rating in a research report on Friday, August 1st. Wall Street Zen downgraded shares of Teleflex from a “strong-buy” rating to a “buy” rating in a report on Monday, September 15th. Wells Fargo & Company dropped their target price on shares of Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Weiss Ratings restated a “sell (d+)” rating on shares of Teleflex in a report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Teleflex from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 30th. One investment analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $141.57.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.